Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MAZE vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Captures Overall Composite Edge (57.8 HOLD vs 34.8 SELL), While MAZE Leads 3–2 on Growth & Valuation Pillars

VOR Overall Winner 6-Pillar Tally: MAZE 3 – 2 VOR (1 Tie) Matrix Metrics: MAZE 4 – 4 VOR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Maze Therapeutics, Inc. (MAZE) on higher Unified Composite conviction (57.8/100 HOLD vs. 34.8/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while MAZE wins 3–2 across the 6-pillar growth and valuation breakdown. MAZE trades at $34.16 (8.5x Forward P/E, -820.8% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. MAZE 34.8/100 SELL) and 1.91β · 61% Vol risk profile, whereas MAZE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MAZE vs VOR
MAZE NASDAQ
Maze Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$34.16
-0.5% 1D
Market Cap $2.0B
TTM Revenue $20M
Forward P/E 8.5x
Beta / 30D Vol 0.78β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 60
RSI-14: 59.6 · SMA20: $33.02 · SMA50: $28.84
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (MAZE 3 – 2 VOR)

Columns: Metric · MAZE · VOR
1. Valuation Multiples MAZE
Forward P/E 8.5x N/M
Trailing P/E 8.5x 0.1x
PEG Ratio N/M N/M
EV / Revenue 98.7x N/M
2. Growth & Scale MAZE
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $20M N/A
Market Cap $2.0B $1.2B
3. Profitability & Quality MAZE
Gross Margin 100.0% N/A
Operating Margin -820.8% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -37.5% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$162M EBITDA -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.59 Book/Sh · -37.5% ROE $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 96.4% (3rd %ile) 127.0% (6th %ile)
Put/Call OI Skew N/A 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MAZE (4) vs VOR (4)
Institutional Metric MAZE VOR Criterion Row Edge
Market Capitalization
Scale
$2.0B $1.2B Larger Scale MAZE
Trailing P/E Ratio
Valuation
8.5x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple MAZE
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-820.8% 0.0% Higher Margin VOR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-37.5% -125.4% Higher ROE MAZE
52-Week Range Position
Momentum
38% ($22–$54) 65% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
0.78β · 54% Vol 1.91β · 61% Vol Lower Realized Risk MAZE
Unified Institutional Score
Composite Signal
34.8 / 100 (SELL) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
$20M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 98.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$162M EBITDA ($7.59 Book/Sh · -37.5% ROE) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MAZE +17.26 pp
MAZE: +24.08% · VOR: +6.82%
3M Horizon MAZE +34.54 pp
MAZE: +17.27% · VOR: -17.27%
6M Horizon MAZE +3.12 pp
MAZE: +39.43% · VOR: +36.31%
1Y Horizon VOR +90.25 pp
MAZE: +7.29% · VOR: +97.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAZE vs VOR. Trailing 12-month operating profitability (MAZE -820.8% vs VOR 0.0%) and valuation multiples (MAZE 8.5x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MAZE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross Margin100.0%
Op. Margin-820.8%
ROE / Fwd P/E-37.5% · 8.5x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MAZE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 96.4%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAZE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MAZE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -820.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MAZE vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Maze Therapeutics, Inc. (MAZE) on higher Unified Composite conviction (57.8/100 HOLD vs. 34.8/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while MAZE wins 3–2 across the 6-pillar growth and valuation breakdown. MAZE trades at $34.16 (8.5x Forward P/E, -820.8% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. MAZE 34.8/100 SELL) and 1.91β · 61% Vol risk profile, whereas MAZE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

MAZE leads the Growth & Scale pillar: MAZE posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (100.0% gross margin, -820.8% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MAZE generates $20M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, MAZE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

MAZE screens cheaper on headline valuation multiples. MAZE trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 98.7x EV/Revenue (unreported EBITDA margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAZE (-37.5% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MAZE carries 96.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.78β · 54% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.